rs397515895
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000256.3(MYBPC3):c.1273C>T(p.Gln425Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. Q425Q) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000256.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.1273C>T | p.Gln425Ter | stop_gained | 15/35 | ENST00000545968.6 | NP_000247.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.1273C>T | p.Gln425Ter | stop_gained | 15/35 | 5 | NM_000256.3 | ENSP00000442795 | P4 | |
MYBPC3 | ENST00000399249.6 | c.1273C>T | p.Gln425Ter | stop_gained | 14/34 | 5 | ENSP00000382193 | A2 | ||
MYBPC3 | ENST00000544791.1 | c.1273C>T | p.Gln425Ter | stop_gained, NMD_transcript_variant | 15/27 | 5 | ENSP00000444259 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1459894Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 726058
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hypertrophic cardiomyopathy Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 30, 2012 | The Gln425X variant in MYBPC3 has been reported in 2 sporadic cases of late-onse t HCM (1 Polish and 1 of unspecified ancestry; Niimura 2002, Radzinski 2008). Th is variant has not been identified in large and broad European American and Afri can American populations by the NHLBI Exome Sequencing Project (http://evs.gs.wa shington.edu/EVS) though it remains possible that this variant is common in othe r populations. This variant leads to a premature termination codon at position 4 25, which is predicted to lead to a truncated or absent protein. Heterozygous lo ss-of-function of the MYBPC3 gene is an established disease mechanism in HCM. In summary, this variant meets our criteria to be classified as pathogenic (http:/ /pcpgm.partners.org/LMM) based on low frequency and the severity of the variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Apr 08, 2020 | This variant has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 11815426, 18803133, 27532257). ClinVar contains an entry for this variant (Variation ID: 42517). For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Gln425*) in the MYBPC3 gene. It is expected to result in an absent or disrupted protein product. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at